Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 8 zilucoplan 7 ravulizumab 6 fludarabine 5 efgartigimod alfa 5 Cyclophosphamide 5 telitacicept 3 Prednisone 3 inebilizumab 2 Rituximab 2 Pyridostigmine Bromide 2 tofacitinib 1 thymoglobulin 1 talquetamab 1 remibrutinib 1 prednylidene 1 iptacopan 1 eculizumab 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Walk Test 1 Therapeutics 1 Tacrolimus 1 Steroids 1 Robotic Surgical Procedures 1 Psychodrama 1 Prednisolone 1 Plasma Exchange 1 Peripheral Blood Stem Cell Transplantation 1 Oxaloacetic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × eculizumab × 1 year × Clear all

NCT06764160 2026-01-15

ECU-MG-304

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡